Shin Nippon Biomedical Laboratories, Ltd. Stock Deutsche Boerse AG

Equities

YB3

JP3379950003

Biotechnology & Medical Research

Market Closed - Deutsche Boerse AG 02:02:25 2024-05-30 EDT 5-day change 1st Jan Change
7.65 EUR +1.32% Intraday chart for Shin Nippon Biomedical Laboratories, Ltd. 0.00% -27.14%

Financials

Sales 2024 26.45B 169M 156M 231M Sales 2025 * 30.5B 194M 179M 266M Capitalization 55.41B 353M 326M 483M
Net income 2024 5.53B 35.27M 32.55M 48.22M Net income 2025 * 4.3B 27.42M 25.31M 37.49M EV / Sales 2024 2.39 x
Net Debt 2024 * 19.51B 124M 115M 170M Net Debt 2025 * 22.77B 145M 134M 199M EV / Sales 2025 * 2.56 x
P/E ratio 2024
11.4 x
P/E ratio 2025 *
12.9 x
Employees 1,341
Yield 2024
3.29%
Yield 2025 *
3.76%
Free-Float 48.8%
More Fundamentals * Assessed data
Dynamic Chart
Shin Nippon Biomedical Laboratories, Ltd. Announces Fiscal Year End Dividend for the Fiscal Year Ended March 31, 2024, Payable on June 25, 2024; Provides Second Quarter End and Fiscal Year End Dividend Guidance for the Fiscal Year Ended March 31, 2025 CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Forecasts for the Six Months Ending September 30, 2024 and Year Ending March 31, 2025 CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024 CI
Shin Nippon's STS101 Faces Regulatory Hurdle, FDA Requests Refinement for Approval MT
Shin Nippon Biomedical Laboratories, Ltd. Announces Interim Dividend for the Year Ending March 31, 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Year Ending March 31, 2024 CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024 CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024 CI
Satsuma Pharmaceuticals and Shin Nippon Biomedical Laboratories, Ltd. Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to Be Presented at the American Headache Society's 65th Annual Scientific Meeting CI
Shin Nippon Biomedical Laboratories, Ltd. completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers. CI
Jefferies Upgrades Shin Nippon Biomedical Laboratories to Buy From Hold, Adjusts Price Target to 2,800 Yen From 2,300 Yen MT
Shin Nippon Biomedical Laboratories, Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024 CI
Shin Nippon Biomedical Laboratories, Ltd. Announces Year End Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023 CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024 CI
Jefferies Downgrades Shin Nippon Biomedical Laboratories to Hold From Buy, Adjusts Price Target to 2,300 Yen From 3,800 Yen MT
More news
1 day+1.32%
Current month-14.53%
1 month-14.53%
3 months-20.73%
6 months-23.12%
Current year-27.14%
More quotes
1 week
7.45
Extreme 7.45
8.00
1 month
7.45
Extreme 7.45
9.10
Current year
7.45
Extreme 7.45
11.90
1 year
7.45
Extreme 7.45
15.60
3 years
5.60
Extreme 5.6
21.60
5 years
3.54
Extreme 3.54
21.60
10 years
2.31
Extreme 2.308
21.60
More quotes
Managers TitleAgeSince
Chief Executive Officer 65 81-08-31
Director of Finance/CFO 55 02-04-30
Compliance Officer - 84-03-31
Members of the board TitleAgeSince
Chief Executive Officer 65 81-08-31
Director/Board Member 38 17-03-31
Sales & Marketing 64 02-10-31
More insiders
Date Price Change
24-05-29 7.55 -5.63%
24-05-28 8 +3.23%
24-05-27 7.75 +4.03%
24-05-24 7.45 -2.61%
24-05-23 7.65 +2.00%

Delayed Quote Deutsche Boerse AG, May 30, 2024 at 02:02 am

More quotes
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1,331 JPY
Average target price
2,800 JPY
Spread / Average Target
+110.37%
Consensus